Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
<Bundle xmlns="http://hl7.org/fhir">
<id value="bundlepackageleaflet-en-77a855e484d10473c2746e9b03c57dde"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"/>
</meta>
<language value="en"/>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="None"/>
</identifier>
<type value="document"/>
<timestamp value="2023-06-27T10:09:22Z"/>
<entry>
<fullUrl
value="Composition/composition-en-77a855e484d10473c2746e9b03c57dde"/>
<resource>
<Composition>
<id value="composition-en-77a855e484d10473c2746e9b03c57dde"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"/>
</meta>
<language value="en"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><a name="Composition_composition-en-77a855e484d10473c2746e9b03c57dde"> </a><p class="res-header-id"><b>Generated Narrative: Composition composition-en-77a855e484d10473c2746e9b03c57dde</b></p><a name="composition-en-77a855e484d10473c2746e9b03c57dde"> </a><a name="hccomposition-en-77a855e484d10473c2746e9b03c57dde"> </a><a name="composition-en-77a855e484d10473c2746e9b03c57dde-en-US"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Language: en</p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/09/604/001-004</p><p><b>status</b>: Final</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}">Package Leaflet</span></p><p><b>category</b>: <span title="Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href="Organization-mah-ema.html">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - leflunomide</p><h3>Attesters</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://hl7.org/fhir/composition-attestation-mode official}">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/09/604/001-004"/>
</identifier>
<status value="final"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package Leaflet"/>
</type>
<category>
<coding>
<system
value="http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs"/>
<code value="R"/>
<display value="Raw"/>
</coding>
</category>
<subject>
<reference
value="MedicinalProductDefinition/mp77a855e484d10473c2746e9b03c57dde"/>
</subject>
<date value="2022-02-16T13:28:17Z"/>
<author>🔗
<reference value="Organization/mah-ema"/>
</author>
<title value="TEST PURPOSES ONLY - leflunomide"/>
<attester>
<mode>
<coding>
<system
value="http://hl7.org/fhir/composition-attestation-mode"/>
<code value="official"/>
</coding>
</mode>
<time value="2022-02-16T13:28:17Z"/>
</attester>
<section>
<title value="B. Package Leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="B. Package Leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
<emptyReason>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
<code value="unavailable"/>
</coding>
</emptyReason>
<section>
<title value="Package leaflet: Information for the user"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package leaflet: Information for the user"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"></div>
</text>
</section>
<section>
<title value="What is in this leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="What is in this leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What is in this leaflet</p><ol type="1"><li>What Leflunomide Zentiva is and what it is used for</li><li>What you need to know before you take Leflunomide Zentiva</li><li>How to take Leflunomide Zentiva</li><li>Possible side effects</li><li>How to store Leflunomide Zentiva</li><li>Contents of the pack and other information</li></ol></div>
</text>
</section>
<section>
<title value="1. What leflunomide is and what it is used for"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="1. What leflunomide is and what it is used for"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Leflunomide Zentiva belongs to a group of medicines called anti-rheumatic medicines. It contains the active substance leflunomide.</p><p>Leflunomide Zentiva is used to treat adult patients with active rheumatoid arthritis or with active psoriatic arthritis.</p><p>Symptoms of rheumatoid arthritis include inflammation of joints, swelling, difficulty moving and pain. Other symptoms that affect the entire body include loss of appetite, fever, loss of energy and anaemia (lack of red blood cells).</p><p>Symptoms of active psoriatic arthritis include inflammation of joints, swelling, difficulty moving, pain and patches of red, scaly skin (skin lesions).</p></div>
</text>
</section>
<section>
<title
value="2. What you need to know before you take leflunomide"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text
value="2. What you need to know before you take leflunomide"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Do not take Leflunomide Zentiva</p><ul><li>if you have ever had an allergic reaction to leflunomide (especially a serious skin reaction, often accompanied by fever, joint pain, red skin stains, or blisters e.g. Stevens-Johnson syndrome) or to any of the other ingredients of this medicine (listed in section 6), or if you are allergic to teriflunomide (used to treat multiple sclerosis),</li><li>if you have any liver problems,</li><li>if you have moderate to severe kidney problems,</li><li>if you have severely low numbers of proteins in your blood (hypoproteinaemia),</li><li>if you suffer from any problem which affects your immune system (e.g. AIDS),</li><li>if you have any problem with your bone marrow, or if you have low numbers of red or white cells in your blood or a reduced number of blood platelets,</li><li>if you are suffering from a serious infection,</li><li>if you are pregnant, think you may be pregnant, or are breast-feeding.</li></ul><p>Warnings and precautions Talk to your doctor, pharmacist or nurse before taking Leflunomide Zentiva</p><ul><li>if you have ever suffered from inflammation of the lung (interstitial lung disease).</li><li>if you have ever had tuberculosis or if you have been in close contact with someone who has or has had tuberculosis. Your doctor may perform tests to see if you have tuberculosis.</li><li>if you are male and wish to father a child. As it can not be excluded that Leflunomide Zentiva passes into semen, reliable contraception should be used during treatment with Leflunomide Zentiva. Men wishing to father a child should contact their doctor who may advise them to stop taking Leflunomide Zentiva and take certain medicines to remove Leflunomide Zentiva rapidly and sufficiently from their body. You will then need a blood test to make sure that Leflunomide Zentiva has been sufficiently removed from your body, and you should then wait for at least another 3 months before attempting to father a child.</li><li></li></ul><p>if you are due to have a specific blood test (calcium level). Falsely low levels of calcium can be detected.</p><p>Leflunomide Zentiva can occasionally cause some problems with your blood, liver, lungs, or nerves in your arms or legs. It may also cause some serious allergic reactions (including Drug Reaction with Eosinophilia and Systemic Symptoms [DRESS]), or increase the chance of a severe infection. For more information on these, please read section 4 (Possible side effects).</p><p>DRESS appears initially as flu-like symptoms and a rash on the face then an extended rash with a high temperature, increased levels of liver enzymes seen in blood tests and an increase in a type of white blood cell (eosinophilia) and enlarged lymph nodes.</p><p>Your doctor will carry out blood tests at regular intervals, before and during treatment with Leflunomide Zentiva, to monitor your blood cells and liver. Your doctor will also check your blood pressure regularly as Leflunomide Zentiva can cause an increase in blood pressure.</p><p>Tell your doctor if you have unexplained chronic diarrhoea. Your doctor may perform additional tests for differential diagnosis.</p><p>Tell your doctor if you develop skin ulcer during treatment with Leflunomide Zentiva (see also section 4).</p><p>Children and adolescents Leflunomide Zentiva is not recommended for use in children and adolescents below 18 years of age.</p><p>Other medicines and Leflunomide Zentiva Please tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This includes medicines obtained without a prescription.</p><p>This is especially important if you are taking:</p><ul><li><p>other medicines for rheumatoid arthritis such as antimalarials (e.g. chloroquine and hydroxychloroquine), intramuscular or oral gold, D-penicillamine, azathioprine and other immunosuppressive medicines (e.g. methotrexate) as these combinations are not advisable,</p></li><li><p>warfarin and other oral medicines used to thin the blood, as monitoring is necessary to reduce the risk of side effects of this medicine</p></li><li><p>teriflunomide for multiple sclerosis</p></li><li><p>repaglinide, pioglitazone, nateglinide, or rosiglitazone for diabetes</p></li><li><p>daunorubicin, doxorubicin, paclitaxel, or topotecan for cancer</p></li><li><p>duloxetine for depression, urinary incontinence or in kidney disease in diabetics</p></li><li><p>alosetron for the management of severe diarrhoea</p></li><li><p>theophylline for asthma</p></li><li><p>tizanidine, a muscle relaxant</p></li><li><p>oral contraceptives (containing ethinylestradiol and levonorgestrel)</p></li><li><p>cefaclor, benzylpenicillin (penicillin G), ciprofloxacin for infections</p></li><li><p>indomethacin, ketoprofen for pain or inflammation</p></li><li><p>furosemide for heart disease (diuretic, water pill)</p></li><li><p>zidovudine for HIV infection</p></li><li><p>rosuvastatin, simvastatin, atorvastatin, pravastatin for hypercholesterolemia (high cholesterol)</p></li><li><p>sulfasalazine for inflammatory bowel disease or rheumatoid arthritis</p></li><li><p>a medicine called colestyramine (used to reduce high cholesterol) or activated charcoal as these medicines can reduce the amount of Leflunomide Zentiva which is absorbed by the body.</p></li></ul><p>If you are already taking a nonsteroidal anti-inflammatory drug (NSAID) and/or corticosteroids, you may continue to take them after starting Leflunomide Zentiva.</p><p>Vaccinations If you have to be vaccinated, ask your doctor for advice. Certain vaccinations should not be given while taking Leflunomide Zentiva, and for a certain amount of time after stopping treatment.</p><p>Leflunomide Zentiva with food, drink and alcohol Leflunomide Zentiva may be taken with or without food. It is not recommended to drink alcohol during treatment with Leflunomide Zentiva. Drinking alcohol while taking Leflunomide Zentiva may increase the chance of liver damage.</p><p>Pregnancy and breast-feeding Do not take Leflunomide Zentiva if you are, or think you may be pregnant. If you are pregnant or become pregnant while taking Leflunomide Zentiva, the risk of having a baby with serious birth defects is increased. Women of childbearing potential must not take Leflunomide Zentiva without using reliable contraceptive measures.</p><p>Tell your doctor if you plan to become pregnant after stopping treatment with Leflunomide Zentiva, as you need to ensure that all traces of Leflunomide Zentiva have left your body before trying to become pregnant. This may take up to 2 years. This may be reduced to a few weeks by taking certain medicines which speed up removal of Leflunomide Zentiva from your body.<br/>In either case it should be confirmed by a blood test that Leflunomide Zentiva has been sufficiently removed from your body and you should then wait for at least another month before you become pregnant.</p><p>For further information on the laboratory testing please contact your doctor.</p><p>If you suspect that you are pregnant while taking Leflunomide Zentiva or in the two years after you have stopped treatment, you must contact your doctor immediately for a pregnancy test. If the test confirms that you are pregnant, your doctor may suggest treatment with certain medicines to remove Leflunomide Zentiva rapidly and sufficiently from your body, as this may decrease the risk to your baby.</p><p>Do not take Leflunomide Zentiva when you are breast-feeding, as leflunomide passes into the breast milk.</p><p>Driving and using machines Leflunomide Zentiva can make you feel dizzy which may impair your ability to concentrate and react. If you are affected, do not drive, or use machines.</p><p>Leflunomide Zentiva contains lactose<br/>If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.</p></div>
</text>
</section>
<section>
<title value="3. How to take leflunomide"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="3. How to take leflunomide"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>The usual starting dose of Leflunomide Zentiva is 100 mg leflunomide once daily for the first three days. After this, most patients need a dose of:</p><ul><li>For rheumatoid arthritis: 10 or 20 mg Leflunomide Zentiva once daily, depending on the severity of the disease.</li><li>For psoriatic arthritis: 20 mg Leflunomide Zentiva once daily.</li></ul><p>Swallow the tablet whole and with plenty of water.</p><p>It may take about 4 weeks or longer until you start to feel an improvement in your condition. Some patients may even still feel further improvements after 4 to 6 months of therapy. You will normally take Leflunomide Zentiva over long periods of time.</p><p>If you take more Leflunomide Zentiva than you should If you take more Leflunomide Zentiva than you should, contact your doctor or get other medical advice. If possible, take your tablets or the box with you to show the doctor.</p><p>If you forget to take Leflunomide Zentiva If you forget to take a dose, take it as soon as you remember, unless it is nearly time for your next dose. Do not take a double dose to make up for a forgotten dose.</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p></div>
</text>
</section>
<section>
<title value="4. Possible side effects"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="4. Possible side effects"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>Tell your doctor immediately and stop taking Leflunomide Zentiva:</p><ul><li><p>if you experience weakness, feel light-headed or dizzy or have difficulty breathing, as these may be signs of a serious allergic reaction,</p></li><li><p>if you develop a skin rash or ulcers in your mouth, as these may indicate severe, sometimes life-threatening reactions (e.g. Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, Drug Reaction with Eosinophilia and Systemic Symptoms [DRESS]), see section 2. Tell your doctor immediately if you experience:</p></li><li><p>pale skin, tiredness, or bruising, as these may indicate blood disorders caused by an imbalance in the different types of blood cells which make up blood,</p></li><li><p>tiredness, abdominal pain, or jaundice (yellow discolouration of the eyes or skin), as these may indicate serious conditions such as liver failure, which may be fatal,</p></li><li><p>any symptoms of an infection such as fever, sore throat or cough, as this medicine may increase the chance of a severe infection which may be life-threatening,</p></li><li><p>cough or breathing problems as these may indicate problems of the lung (interstitial lung disease or pulmonary hypertension),</p></li><li><p>unusual tingling, weakness or pain in your hands or feet as these may indicate problems with your nerves (peripheral neuropathy).</p></li></ul><p>Common side effects (may affect up to 1 in 10 people)</p><ul><li><p>a slight decrease in the number of white blood cells (leucopenia),</p></li><li><p>mild allergic reactions,</p></li><li><p>loss of appetite, weight loss (usually insignificant),</p></li><li><p>tiredness (asthenia),</p></li><li><p>headache, dizziness,</p></li><li><p>abnormal skin sensations like tingling (paraesthesia),</p></li><li><p>mild increase in blood pressure,</p></li><li><p>colitis,</p></li><li><p>diarrhoea,</p></li><li><p>nausea, vomiting,</p></li><li><p>inflammation of the mouth or mouth ulcers,</p></li><li><p>abdominal pain,</p></li><li><p>an increase in some liver test results,</p></li><li><p>increased hair loss,</p></li><li><p>eczema, dry skin, rash, itching,</p></li><li><p>tendonitis (pain caused by inflammation in the membrane surrounding the tendons usually in the feet or hands),</p></li><li><p>an increase of certain enzymes in the blood (creatine phosphokinase),</p></li><li><p>problems in the nerves of the arms or legs (peripheral neuropathy).</p></li></ul><p>Uncommon side effects (may affect up to 1 in 100 people)</p><ul><li>a decrease in the number of red blood cells (anaemia) and a decrease in the number of blood platelets (thrombocytopenia),</li><li>a decrease in the levels of potassium in the blood,</li><li>anxiety,</li><li>taste disturbances,</li><li>urticaria (nettle rash),</li><li>tendon rupture,</li><li>an increase in the levels of fat in the blood (cholesterol and triglycerides),</li><li>a decrease in the levels of phosphate in the blood.</li></ul><p>Rare side effects (may affect up to 1 in 1,000 people)</p><ul><li>an increase in the numbers of blood cells called eosinophiles (eosinophilia); mild decrease in the number of white blood cells (leucopenia); decrease in the number of all blood cells (pancytopenia),</li><li>severe increase in blood pressure,</li><li>inflammation of the lung (interstitial lung disease),</li><li>an increase in some liver results which may develop into serious conditions such as hepatitis and jaundice,</li><li>severe infections called sepsis which may be fatal,</li><li>an increase of certain enzymes in the blood (lactate dehydrogenase).</li></ul><p>Very rare side effects (may affect up to 1 in 10,000 people)</p><ul><li>a marked decrease of some white blood cells (agranulocytosis),</li><li>severe and potentially severe allergic reactions,</li><li>inflammation of blood vessels (vasculitis, including cutaneous necrotizing vasculitis),</li><li>inflammation of the pancreas (pancreatitis),</li><li>severe liver injury such as liver failure or necrosis which may be fatal,</li><li>severe sometimes life-threatening reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme).</li></ul><p>Other side effects such as kidney failure, a decrease in the levels of uric acid in your blood, pulmonary hypertension, male infertility (which is reversible once treatment with this medicine is stopped), cutaneous lupus (characterized by rash/erythema on skin areas that are exposed to light), psoriasis (new or worsening), DRESS and skin ulcer (round, open sore in the skin through which the underlying tissues can be seen), may also occur with an unknown frequency.</p><p>Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.</p></div>
</text>
</section>
<section>
<title value="5. How to store leflunomide"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="5. How to store leflunomide"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the packaging. The expiry date refers to the last day of that month.</p><p>Blister: Store in the original package.</p><p>Bottle: Keep the bottle tightly closed.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p></div>
</text>
</section>
<section>
<title value="6. Contents of the pack and other information"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="6. Contents of the pack and other information"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What Leflunomide Zentiva contains</p><ul><li>The active substance is leflunomide. One film-coated tablet contains 10 mg of leflunomide.</li><li>The other ingredients are: maize starch, povidone (E1201), crospovidone (E1202), silica colloidal anhydrous, magnesium stearate (E470b), and lactose monohydrate in the tablet core, as well as talc (E553b), hypromellose (E464), titanium dioxide (E171), and macrogol 8000 in the film-coating.</li></ul><p>What Leflunomide Zentiva looks like and contents of the pack Leflunomide Zentiva 10 mg film-coated tablets are white to almost white and round. Imprint on one side: ZBN.</p><p>The tablets are packed in blisters or bottles. Packs of 30 and 100 tablets are available.</p><p>Not all pack size may be marketed.</p><p>Marketing Authorisation Holder Zentiva k.s.<br/>U kabelovny 102 37 Prague Czech Republic</p><p>Manufacturer<br/>Opella Healthcare International SAS 56, Route de Choisy 60200 Compi gne France</p><p>For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder.</p><p>Belgi /Belgique/Belgien Zentiva, k.s. T l/Tel: +32 280 86 <a href="mailto:PV-Belgium@zentiva.com">PV-Belgium@zentiva.com</a></p><p>Lietuva Zentiva, k.s. Tel: +370 <a href="mailto:52152PV-Lithuania@zentiva.com">52152PV-Lithuania@zentiva.com</a></p><p>Zentiva, k.s. : <a href="mailto:+35924417PV-Bulgaria@zentiva.com">+35924417PV-Bulgaria@zentiva.com</a></p><p>Luxembourg/Luxemburg Zentiva, k.s. T l/Tel: +352 208 <a href="mailto:82PV-Luxembourg@zentiva.com">82PV-Luxembourg@zentiva.com</a> esk republika Zentiva, k.s. Tel: +420 267 241 <a href="mailto:PV-Czech-Republic@zentiva.com">PV-Czech-Republic@zentiva.com</a></p><p>Magyarorsz g Zentiva Pharma Kft. Tel.: +36 1 299 <a href="mailto:1PV-Hungary@zentiva.com">1PV-Hungary@zentiva.com</a> Danmark Zentiva Denmark ApS Tlf: +45 787 68 <a href="mailto:PV-Denmark@zentiva.com">PV-Denmark@zentiva.com</a></p><p>Malta Zentiva, k.s. Tel: +356 2778 <a href="mailto:0PV-Malta@zentiva.com">0PV-Malta@zentiva.com</a> Deutschland Zentiva Pharma GmbH<br/>Tel: +49 (0) 800 53 53 <a href="mailto:PV-Germany@zentiva.com">PV-Germany@zentiva.com</a></p><p>Nederland Zentiva, k.s. Tel: +31 202 253 <a href="mailto:PV-Netherlands@zentiva.com">PV-Netherlands@zentiva.com</a> Eesti Zentiva, k.s. Tel: +372 52 <a href="mailto:70PV-Estonia@zentiva.com">70PV-Estonia@zentiva.com</a></p><p>Norge Zentiva Denmark ApS Tlf: +47 219 66 <a href="mailto:PV-Norway@zentiva.com">PV-Norway@zentiva.com</a></p><p>Zentiva, k.s. : +30 211 198 <a href="mailto:7PV-Greece@zentiva.com">7PV-Greece@zentiva.com</a></p><p>sterreich Zentiva, k.s. Tel: +43 720 778 <a href="mailto:PV-Austria@zentiva.com">PV-Austria@zentiva.com</a> Espa a Zentiva, k.s. Tel: +34 931 815 <a href="mailto:PV-Spain@zentiva.com">PV-Spain@zentiva.com</a></p><p>Polska Zentiva Polska Sp. z o.o. Tel: + 48 22 375 92 <a href="mailto:PV-Poland@zentiva.com">PV-Poland@zentiva.com</a> France Zentiva France T l: +33 (0) 800 089 <a href="mailto:PV-France@zentiva.com">PV-France@zentiva.com</a></p><p>Portugal Zentiva Portugal, Lda Tel: <a href="mailto:+351210601PV-Portugal@zentiva.com">+351210601PV-Portugal@zentiva.com</a></p><p>Hrvatska Zentiva d.o.o. Tel: +385 1 6641 <a href="mailto:PV-Croatia@zentiva.com">PV-Croatia@zentiva.com</a></p><p>Ireland Zentiva, k.s. Tel: +353 818 882 <a href="mailto:PV-Ireland@zentiva.com">PV-Ireland@zentiva.com</a></p><p>Rom nia ZENTIVA S.A. Tel: +4 <a href="mailto:021.304.7PV-Romania@zentiva.com">021.304.7PV-Romania@zentiva.com</a></p><p>Slovenija Zentiva, k.s. Tel: +386 360 00 <a href="mailto:PV-Slovenia@zentiva.com">PV-Slovenia@zentiva.com</a> sland Zentiva Denmark ApS S mi: +354 539 <a href="mailto:0PV-Iceland@zentiva.com">0PV-Iceland@zentiva.com</a></p><p>Slovensk republika Zentiva, a.s. Tel: +421 2 3918 <a href="mailto:3PV-Slovakia@zentiva.com">3PV-Slovakia@zentiva.com</a> Italia Zentiva Italia S.r.l. Tel: <a href="mailto:+39-02-38598PV-Italy@zentiva.com">+39-02-38598PV-Italy@zentiva.com</a> Suomi/Finland Zentiva Denmark ApS Puh/Tel: +358 942 598 <a href="mailto:PV-Finland@zentiva.com">PV-Finland@zentiva.com</a></p><p>Zentiva, k.s. : +357 240 30 <a href="mailto:PV-Cyprus@zentiva.com">PV-Cyprus@zentiva.com</a></p><p>Sverige Zentiva Denmark ApS Tel: +46 840 838 <a href="mailto:PV-Sweden@zentiva.com">PV-Sweden@zentiva.com</a> Latvija Zentiva, k.s. Tel: +371 <a href="mailto:67893PV-Latvia@zentiva.com">67893PV-Latvia@zentiva.com</a></p><p>United Kingdom (Northern Ireland) Zentiva, k.s. Tel: +44 (0) 800 090 <a href="mailto:2PV-United-Kingdom@zentiva.com">2PV-United-Kingdom@zentiva.com</a></p><p>This leaflet was last revised in {MM/YYYY}</p><p>Other sources of information Detailed information on this medicine is available on the European Medicines Agency web site:</p></div>
</text>
</section>
</section>
</Composition>
</resource>
</entry>
<entry>
<fullUrl
value="MedicinalProductDefinition/mp77a855e484d10473c2746e9b03c57dde"/>
<resource>
<MedicinalProductDefinition>
<id value="mp77a855e484d10473c2746e9b03c57dde"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"/>
</meta>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><a name="MedicinalProductDefinition_mp77a855e484d10473c2746e9b03c57dde"> </a><p class="res-header-id"><b>Generated Narrative: MedicinalProductDefinition mp77a855e484d10473c2746e9b03c57dde</b></p><a name="mp77a855e484d10473c2746e9b03c57dde"> </a><a name="hcmp77a855e484d10473c2746e9b03c57dde"> </a><a name="mp77a855e484d10473c2746e9b03c57dde-en-US"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/09/604/001-004</p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}">Medicinal Product</span></p><p><b>domain</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-domain Human}">Human use</span></p><p><b>status</b>: <span title="Codes:{http://hl7.org/fhir/publication-status active}">active</span></p><p><b>legalStatusOfSupply</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi 100000072084}">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: Leflunomide Zentiva 10 mg film-coated tablets</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:ietf:bcp:47 en}">en</span></td></tr></table></blockquote></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/09/604/001-004"/>
</identifier>
<type>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-type"/>
<code value="MedicinalProduct"/>
<display value="Medicinal Product"/>
</coding>
</type>
<domain>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-domain"/>
<code value="Human"/>
<display value="Human use"/>
</coding>
</domain>
<status>
<coding>
<system value="http://hl7.org/fhir/publication-status"/>
<code value="active"/>
<display value="active"/>
</coding>
</status>
<legalStatusOfSupply>
<coding>
<system value="https://spor.ema.europa.eu/rmswi"/>
<code value="100000072084"/>
<display
value="Medicinal product subject to medical prescription"/>
</coding>
</legalStatusOfSupply>
<name>
<productName value="Leflunomide Zentiva 10 mg film-coated tablets"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000001"/>
<display value="Full name"/>
</coding>
</type>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000002"/>
<display value="Invented name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000003"/>
<display value="Scientific name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000004"/>
<display value="Strength part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000005"/>
<display value="Pharmaceutical dose form part"/>
</coding>
</type>
</part>
<usage>
<country>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</country>
<jurisdiction>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</jurisdiction>
<language>
<coding>
<system value="urn:ietf:bcp:47"/>
<code value="en"/>
<display value="en"/>
</coding>
</language>
</usage>
</name>
</MedicinalProductDefinition>
</resource>
</entry>
</Bundle>
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
